About - BioWorld
WEBBioWorld remains committed to the core principles of ethical journalism, producing fact-based news and analysis via direct interviews with sources and intensive background research bolstered with invaluable data from BioWorld’s vast archives and other trusted data sources. We are constantly working to enhance our news products.
| BioWorld
WEBAug 30, 2002 · Alliance Pharmaceutical Corp. has spent more than $200 million developing its intravascular oxygen carrier, Oxygent. But now facing a revised development plan that it cannot afford, Alliance cut 40 percent of its work force and warned PFC Therapeutics LLC, the joint venture set up to commercialize the product, that if funds don't materialize, the Oxygent license agreement will be terminated ...
Dupixent atopic of talk as Galderma’s Nemluvio cleared in PN
WEBAug 13, 2024 · Aiming to offer an advantage over Dupixent (dupilumab, Regeneron Pharmaceuticals Inc.), dermatology-focused Galderma Holding SA won clearance from the U.S. FDA for Nemluvio (nemolizumab) as a prefilled pen providing a subcutaneous injection to treat adults with prurigo nodularis (PN). Cumulus Oncology Ltd. is …
License - BioWorld
WEBAug 20, 2024 · Ensho Therapeutics Inc. launched in July after licensing a pipeline of four oral α4β7 inhibitors for inflammatory and gastrointestinal disorders, including inflammatory bowel disease (IBD), from EA Pharma Co. Ltd. “Millions of people worldwide are living with IBD,” Ensho founder, president and executive chair Neena Bitritto-Garg recently told BioWorld, “and while there are a number of ...
Stop interleukin-11 to age better and live longer - BioWorld
WEBJul 24, 2024 · Although there is no single answer, scientists at Duke-National University of Singapore (NUS) have shown in mice that interleukin-11 (IL-11) promoted aging. Blocking it improved health and lifespan. Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of sourcing novel drug targets emerging from academia ...
Cresilon Traumagel wins FDA greenlight | BioWorld
WEBAug 21, 2024 · Cresilon Inc. secured U.S. FDA clearance for Traumagel, a hydrogel that stops potentially life-threatening bleeding in seconds. Cresilon designed the product for use by the U.S. military, first responders and medical professionals to swiftly and effectively stop bleeding from traumatic wounds
AACR 2022: Understanding cancer’s brain is new …
WEBApr 14, 2022 · The tumor microenvironment is critical for the ability of cancers to survive and grow, and some aspects of the microenvironment are studied, and targeted, accordingly. Tumor immunology is one of the most active areas of cancer research and has become a pillar of treatment. Others, not so much. “The nervous system is the last component of the microenvironment that people have left completely ...
Structural study gives insights into influenza virus species jumps
WEBAug 20, 2024 · “There are hundreds of strains of bird flu, and most of them don’t infect humans, or even mammals,” Stephen Cusack told BioWorld. “There are two main reasons for that.” To be able to cause an infection, a virus “has to be able to get into the cell, and for that it needs a receptor,” Cusack said. For influenza viruses, those receptors are hemagglutinin receptors, and they differ ...
Cumulus Oncology licenses small molecules from GPR68 drug
WEBAug 20, 2024 · Cumulus Oncology Ltd. has announced key milestones, in partnership with collaborator Leadxpro AG, in the companies’ protein structure-driven GPR68 drug discovery project. The partners announced their collaboration in July last year to develop small molecules against GPR68.
Neurology/psychiatric - BioWorld
WEBSep 10, 2024 · ML-218 is an orally active, selective, and potent T-type calcium channel (Cav3.1, Cav3.2 and Cav3.3) inhibitor. Previous research has shown that ML-218 penetrates the blood-brain barrier and exerts protective effects against haloperidol-induced catalepsy, peripheral neuropathy and Parkinson’s disease.
Skip to content